Novo Nordisk's brand name for semaglutide approved specifically for weight management, given as a weekly injection (an oral version arrived later). It shares its active ingredient with Ozempic but carries the weight-loss label and has a completed cardiovascular outcomes trial behind it. It's one of the two most-prescribed weight-management GLP-1s, alongside Zepbound.
Related terms: Semaglutide · Ozempic · Zepbound · Cardiovascular outcomes trial (CVOT)
See also: Wegovy vs. Zepbound